Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569624 | 1.00 | BRD4 (0.56) | BRD4TP53MAPTCASP3SENP8 | |
| SCHEMBL13415304 | 0.83 | TP53 (0.64) | TP53MAPTCASP3SENP8SENP7 | |
| SCHEMBL23107977 | 0.81 | BRD4 (0.52) | BRD4TP53MAPTCASP3SENP8 | |
| SCHEMBL23107978 | 0.81 | BRD4 (0.49) | BRD4TP53MAPTCASP3SENP8 | |
| SCHEMBL23058985 | 0.80 | ACHE (0.61) | BRD4TP53MAPTACHEPARP1 | |
| SCHEMBL12494 | 0.78 | RAB9A (0.64) | TP53MAPTCASP3SENP8SENP7 | |
| SCHEMBL2618900 | 0.77 | TP53 (0.70) | TP53MAPTACHENPC1RAB9A | |
| SCHEMBL138239 | 0.77 | NPC1 (0.59) | TP53MAPTACHEPARP1NPC1 | |
| SCHEMBL13167092 | 0.77 | TP53 (0.70) | TP53MAPTCASP3SENP7ACHE | |
| SCHEMBL16579451 | 0.77 | TP53 (0.70) | TP53MAPTCASP3SENP7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2003048121-A1 | THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | APOB, APOL1, TTR | BRD4 953/4885TP53 3779/4885MAPT 1281/4885 |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | BRD4 3982/4885TP53 349/4885MAPT 3793/4885 |
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | BRD4 1378/4885TP53 4752/4885MAPT 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.